WO2007025554A1 - Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes - Google Patents

Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes Download PDF

Info

Publication number
WO2007025554A1
WO2007025554A1 PCT/EP2005/009289 EP2005009289W WO2007025554A1 WO 2007025554 A1 WO2007025554 A1 WO 2007025554A1 EP 2005009289 W EP2005009289 W EP 2005009289W WO 2007025554 A1 WO2007025554 A1 WO 2007025554A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
antigen
cell line
specific
Prior art date
Application number
PCT/EP2005/009289
Other languages
English (en)
Inventor
Tim Greten
Firouzeh Korangy
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Priority to PCT/EP2005/009289 priority Critical patent/WO2007025554A1/fr
Priority to PCT/EP2006/008421 priority patent/WO2007025705A2/fr
Publication of WO2007025554A1 publication Critical patent/WO2007025554A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Definitions

  • the present invention relates to the generation and expansion of antigen-specific T- cells. Furthermore, the present invention relates to the use of antigen-specific T-cells obtained with the method according to the present invention in adoptive cell transfer therapy and in the treatment of various disorders and diseases including infections and cancer. Moreover, the present invention provides for kits and its use for generating and expanding antigen-specific T-cells. The present invention allows for the generation of antigen-specific T-cells suitable for adoptive cell transfer. The methods for the generation and expansion of antigen-specific T-cells include both in vitro and in vivo approaches.
  • the immune system represents the defence system present in its most advanced form in higher vertebrates.
  • the immune system provides rapid and specific responses on all kinds of foreign substances. These foreign substances, known as antigens, release from the surface of the lymphocytes, mainly the B-cells and T-cells, signals for cellular or humoral immune responses.
  • the T-cells are responsible for the cellular immune response while the antibody producing B-lymphocytes supported by specific T-cells are the main component of the humoral response.
  • an errant immune response is also responsible for autoimmune diseases or transplant tissue rejection.
  • T-cells are one of the major regulatory cell types of the immune system.
  • the regulatory functions of T-cells depend not only on expression of a unique T-cell receptor, but also on expression of a variety of accessory molecules and effector functions associated with an individual T-cell response, e.g. T-helper cells versus cytotoxic T-cells.
  • Each individual T-cell expresses a unique T-cell receptor. After clonal expansion of this individual T-cell, a number of identical T-cells are obtained displaying the same individual T-cell receptor having a specific antigenicity for an antigenic structure. It is the regulatory function of T-cells that often goes awry in the development of autoimmune diseases, plays a large role in tissue graft rejection, and can be important in tumour rejection.
  • T cells express a unique T-cell receptor (TCR).
  • TCR T-cell receptor
  • the cognate ligands are antigen containing major histocompatibility complex molecules (MHC), the MHC complex. That is, the TCR which is expressed on a T-cell surface recognizes the antigen present in form of a small antigenic peptide presented by the MHC molecules on the surface of the so called antigen presenting cells (APC).
  • MHC major histocompatibility complex molecules
  • the MHC molecules can be divided mainly into the MHC class I and MHC class Il molecules.
  • the MHC molecules are encoded by a large complex of multiple genes, many of which are highly polymorphic. Thus, the variability of the MHC system is achieved in each individual by a multigenic system.
  • the class I molecules consist of a heavy peptide chain noncovalently linked to a smaller peptide called ⁇ 2- microglobulin. The largest part of the heavy chain is organized into three globular domains ( ⁇ 1, ⁇ 2, and ⁇ 3) which protrude from the cell surface; a hydrophobic section anchors the molecule in the membrane and a short hydrophilic sequence carries the C-terminus into the cytoplasm.
  • This cavity or groove formed by these two domains contains the antigenic structure, e.g. the peptide derived from the foreign substance.
  • the class Il molecules are also transmembrane glycoproteins consisting of an ⁇ and a ⁇ polypeptide chain.
  • the ⁇ 1 and the ⁇ 1 domains form the groove responsible for the uptake and representation of the antigenic structure.
  • MHC class Il molecules are expressed by antigen presenting cells, like dendritic cells, macrophages and B-cells. MHC class I molecules are responsible for an immune response involving cytotoxic T-cells. That is, the MHC class I molecules contain antigenic structures present in the cytosol of the cells, i.e. endogenous cytosolic molecules. In contrast, the MHC class Il molecules present exogenous molecules to the T-cells of the helper-type. In the most recent years the adoptive cell-transfer therapy comes into the focus as an instrument for the treatment of e.g. cancer and in transplantation.
  • This type of therapy is based on the use of antigen-specific T-cells as the inducer of an immune response against tumours or infections.
  • cytotoxic T-cells represent the ultimate effector mediating the rejection of tumour cells or cells infected with foreign invaders like bacteria, parasites or virus.
  • one major hurdle in adoptive cell-transfer therapy before administering cells to the patient is the generation of a sufficient number of antigen-specific cells.
  • the generation and expansion of the antigen-specific cells is conducted in vitro, although in vivo expansion is also possible.
  • the expansion of T-cells may be effected specifically or unspecifically.
  • antigen-specific T-cells specific for the antigenic structure have to be prepared.
  • the specificity of the antigen-specific T-cells against the foreign infection or the tumour cells is essential for attaining a successful therapy.
  • one major problem is the efficient production of a sufficient number of antigen-specific T-cells for later transfer into the recipient.
  • dendritic cells as the antigen presenting cell pulsed or loaded with the defined peptide(s) of interest.
  • PBMC peripheral blood mononuclear cells
  • Dendritic cells are considered to be the most important antigen presenting cells in the immune system. They sample antigen at the body's environmental interface and, under appropriate conditions, mature and migrate to the lymphatic organs were they induce primary and enhance secondary immune responses.
  • dendritic cells are regarded as the primary antigen presenting cell system in humans because of their wide application in presenting primary antigen to cells.
  • Self or foreign proteins are processed within a dendritic cell (DC) including processing system comprising the TAP molecules.
  • the resultant peptide epitopes are presented by MHC molecules, and are transported to the surface of the DC.
  • DCs in an approach to generate antigen-specific T-cells does not necessarily result in the same specificity of the antigen-specific T-cells. That means, using the same DC and the same antigen does not lead to the same antigen-specific T-cells but different clones may be obtained recognizing different epitopes of the antigen.
  • pulsing the DC with the desired antigen would not lead the DC presenting only epitopes of the desired antigen but also other molecules may be presented in the MHC molecules of the DC.
  • the response of the T-helper cells may be of the T-helper-1 type or the T-helper-2 type. Further, under appropriate conditions an unpolarized Th-O response can be induced or the cultivation with dendritic cells may anergize the T-cells which results in tolerance.
  • the mechanisms involved in this plasticity are affinity and duration of MHC H-TCR (t-cell receptor) interaction, the expression pattern of costimulatory molecules, and the availability of cytokines.
  • antigen-pulsed dendritic cells i.e. DC loaded with antigens.
  • antigen-pulsed DC i.e. DC loaded with antigens.
  • Another object of the invention is to provide a method for the fast and reliable generation and expansion of antigen-specific T-cells.
  • Another object of the invention is the provision of overcoming the laborious work of generating DC cells for the co-culture and stimulation of antigen-specific T-cells and the provision of a sufficient amount of APC for the generation of antigen-specific T-cells.
  • the present inventors now discovered that the use of cells which are phenotypically negative for a functional MHC class I and/or class Il complex being transformed or transfected with a construct leading to the expression of functional MHC class I and/or class Il complexes containing the antigenic structure of the peptide of interest (POI) allows for the production of antigen-specific T-cells whether T-helper cells or cytotoxic T-cells. These cells will also be referred to as artificial antigen presenting cells or aAPC. Thus, the above cells do present a single antigenic structure to the immune competent cells, in particular to the T-cells.
  • POI peptide of interest
  • a method for the generation and expansion of antigen-specific T-cells comprising the steps of: a. providing a cell or cell line being phenotypically negative for a functional
  • a construct comprising (i) a peptide of interest (POI) comprising an antigenic structure, (ii) at least one spacer and (iii) an MHC molecule or parts thereof or sequences encoding (i), (ii) and/or (iii) into the cell or cell line of a.); c. obtaining a cell or cell line (aAPC) expressing a peptide construct comprising the antigenic structure presented by the MHC complex as defined in b) on their surface; d. co-culturing the cell or cell line obtained in c.) with cells comprising T-cells; and e. expanding antigen-specific T-cells specific for the antigenic structure of the POI present in the construct as defined in b.).
  • POI peptide of interest
  • the cells obtained in step c.) which are characterized in functionally expressing a peptide construct comprising a peptide of interest including an antigenic structure, a spacer in between the peptide of interest and an MHC molecule are recombinantly obtained cells which are also referred to as artificial antigen presenting cells aAPC, as POI presenting cells or peptide-MHC-APC.
  • Th cells refers to Helper T cells, CD4+.
  • CTL refers to cytotoxic T-cells, CD8+.
  • MHC major histocompatibility complex
  • HLA human leucocyte antigens
  • MHC molecule refers to MHC molecules themselves or functional fragments thereof which molecules or functional fragments are able to induce an antigen specific activation of cells expressing receptor molecules for the MHC molecule, like cells expressing the B-cell receptor or the T-cell receptor when these molecule or fragments are expressed in combination with a molecule, preferably a peptide, containing an antigenic structure, said combination of MHC molecule and antigenic structure, the MHC complex, is specifically recognized by the B-cell receptor or T-cell receptor, respectively.
  • adoptive immunotherapy or “adoptive cell transfer” refers the administration of donor or autologous T-lymphocytes for the treatment of a disease or disease condition, wherein the disease condition results in an insufficient or inadequate immune response that is normally associated with Class I or Class Il MHC molecules, in particular with Class I or Class Il HLA molecules.
  • Adoptive immunotherapy is an appropriate treatment for any disease or disease condition where the elimination of infected or transformed cells has been demonstrated to be achieved by CTLs or T helper cells.
  • Disease or disease conditions as used herein include but are not limited to cancer and/or tumours, such as, melanoma, prostate, breast, colorectal, stomach, throat and neck, pancreatic, cervical, ovarian, bone, leukemia and lung cancer; viral infections, such as, hepatitis B, hepatitis C, human immunodeficiency virus; bacterial infections, such as tuberculosis, leprosy and listeriosis, and parasitic infections such as malaria.
  • the adoptive immunotherapy or adoptive cell transfer is useful in transplantation, like organ graft rejection or diseases associated with an transplantation like EBV or CMV infection.
  • epitope refers to a structure, like a peptide, derived from an antigen capable of causing a cellular or humoral immune response in a mammal.
  • Such structures may also be reactive with antibodies from an animal immunized with the structures.
  • peptides may be about five to twenty amino acid in length preferably about eight to fifteen amino acids in length, and most preferably about nine to ten amino acids in length.
  • the media for the co-culture of the transformed or transfected cells obtained in step c), the aAPC, with cells comprising T-cells according to step d.) may further contain growth factors, cytokines, and/or substances, in particular salts, nutrients, or other auxiliary agents and/or drugs.
  • Co-culture is conducted in suitable containers, like culture dishes or flasks.
  • the medium is a AB-medium characterized in that the FCS usually present in fully supplemented medium is substituted with AB-sera.
  • the culture conditions are preferably 37 0 C and 5% CO2 atmosphere.
  • the cells obtained in step c), the aAPC, and the cells comprising T-cells to be cultured with the aAPC are cultured under conditions allowing for expansion of antigen-specific T-cells with appropriate co- molecules depending on which type of T-cells should be expanded.
  • Another preferred embodiment comprises the step of pre-stimulation of the aAPC obtained in step c.) with appropriate factors to induce expression of co-stimulatory molecules.
  • a pre- stimulation of transfected Daudi cells is conducted by cultivating said cells in a medium containing IL-4 and CD40L. After pre-stimulation, the stimulated aAPC are co-cultured with cells comprising T-cells according to step d.) of the present invention.
  • the co-cultivation according to step d.) and the expansion step e.) of the method according to the present invention is repeated at least once, more preferably, twice or more.
  • the aAPC obtained in step c) of the method described above may be obtained by a selection step or an enrichment step.
  • the selection step may be any kind of selection of the desired transfected cell based on selection markers known in the art.
  • suitable selection markers are, for example, resistances to antibiotics such as ampicillin, kanamycin, neomycin, puromycin, zeocin, blastomycin or metabolic defects.
  • GFP/EGF expressing constructs for selection e.g. for sorting transfected cells can be applied.
  • antigen-specific T-cells in large amounts and in high purity can be harvested from the culture which may include a further purification step.
  • These antigen-specific T-cells may be used further for various applications. These further applications include the adoptive immunotherapy or the adoptive cell transfer, respectively.
  • the cells may be useful for the treatment of cancer, allergic disorders, infectious diseases, autoimmune disorders and host versus graft or graft versus host reactions in transplantation.
  • the origin of the T-cells is mostly the blood of donors. However, since the number of the desired cell type, the antigen-specific T-cells, is very low an expansion step for theses cells is necessary.
  • the cells containing T-cells to be cultured with transformed or transfected cell or cell line, the aAPC are derived from the recipient himself or may be derived from a healthy volunteer.
  • frozen cells may be used. Said frozen cells may be derived from the recipient of the adoptive cell-transfer therapy.
  • blood mononuclear cells in particular peripheral blood mononuclear cells or peripheral blood lymphocytes are used for cultivation. Particularly, the cells are of human origin.
  • the cell used for the preparation of the artificial antigen presenting cell is a cell or cell line being phenotypically negative for a functional MHC class I and/or class Il complex.
  • the term "being phenotypically negative for a functional MHC class 1 and/or MHC class Il complex” refers to a cell or cell line which do not express an MHC class I or class Il complex on their cell surface containing an antigenic structure.
  • functional complex means a complex composed of the MHC molecule and the antigenic structure present in the groove of the MHC molecule. That is, the cell or cell line may be defective in expressing any functional self MHC class I or class Il molecules, e.g. by a genetic defect.
  • the cell or cell line is a cell or dell line which does not express any self MHC class I or MHC class Il at all.
  • the expression of the self MHC class I and/or class Il molecule is suppressed by means known in the art. For example, suppression is effected by siRNA-techniques.
  • the TAP molecules involved in the processing of antigen may be inactivated or its expression may be suppressed.
  • the expression of the invariant chain may be disrupted, inhibiting the formation of self MHC class Il complexes.
  • the cell or cell line do express an MHC class I and/or class Il molecule which does not contain an antigenic structure. This can be achieved for example by antigen stripping or by manipulating the self MHC class I and/or class Il proteins in a way that no antigenic structure can assemble in the groove.
  • Rendering the cell or cell being negative for a functional MHC class I and/or class Il complex may be effected after transfection with the construct comprising the POI, at least one spacer and MHC molecule or parts thereof.
  • the antigenic structure present in the construct introduced into the cell or cell line is a part of or the complete peptide of interest.
  • the term "peptide of interest, POI" refers to the peptide the antigen-specific T-cells are raised against. That is, in case of foreign invaders, the peptide of interest contains an antigenic structure specific for the foreign invader which will elicit an immune response in the subject.
  • the antigenic structure expressed in connection with the MHC complex on the cell or cell line, the aAPC is derived from tumour associated antigens.
  • the antigenic structure is derived from viral or bacterial antigens, respectively.
  • the antigenic structure is an antigenic structure derived from the "self-antigen" causative of the autoimmune disease. The same is true for allergic disorders where for the treatment of the antigenic structure the antigenic structure of the causative allergen is used as the POI in the construct.
  • the POI is the influenza M1 peptide as described in Greten et al., J. Immunol. Meth., 2002, 125-135.
  • the POI may be derived from tumour antigens, like the NY-ESO-Epitope, SLLMWITQC, an Epitope well known in the art.
  • the construct introduced into the cell or cell line is a DNA- construct. Suitable constructs are described for example in Greten TF, et al, J. Immunol. Meth., 2002, 125-135 which is enclosed herewith by reference in its entirety.
  • the construct is composed of a nucleic acid sequence encoding a peptide comprising an antigenic structure, spacer, optionally ⁇ 2-microgloblin, and at least parts of the MHC class I molecule.
  • the construct has the following order of components, starting from the N-terminus: Leader sequence of the ⁇ 2 microglobulin, the POI, a spacer, ⁇ 2 microglobulin core sequence, a spacer, MHC class I sequence. This preferred embodiment is also shown in figure 1.
  • the construct is composed of a nucleic acid sequence encoding a peptide comprising an antigenic structure, spacer, and at least parts of the MHC class Il molecule.
  • Suitable viral expression systems are, for example, the bacculovirus system, e.g. BacculoGold (BD Bioscience Pharmingen, Palo Alto, CA, USA), adenoviral expression systems such as, for example, ViraPortTM (Stratagene, La JoIIa, CA, USA), retroviral expression systems such as, for example, AdEasy (Stratagene, La JoIIa, CA, USA) etc.
  • BacculoGold BD Bioscience Pharmingen, Palo Alto, CA, USA
  • adenoviral expression systems such as, for example, ViraPortTM (Stratagene, La JoIIa, CA, USA)
  • retroviral expression systems such as, for example, AdEasy (Stratagene, La JoIIa, CA, USA) etc.
  • the transfection is a stable transfection and not a transient transfection since it is necessary to culture the obtained transfected cells over a long period of time.
  • the construct introduced into the cell or cell line may be a peptide molecule.
  • Introduction of the peptide can be achieved by known methods.
  • introduction of the peptide can be achieved by using a translocation or targeting sequence known in the art.
  • translocation sequences are linked to the molecules to be transported (also called cargo molecules) either via covalent or via noncovalent linkages. Extracellular addition of the resulting compounds of translocation sequence and cargo molecule to cells is then possible.
  • the translocation sequence facilitates the entry of the cargo molecule into the interior of the cell. This principle has likewise been described in numerous studies, especially for the HIV Tat sequence.
  • translocation sequences include viral sequences, homeoprotein sequences, leucine zipper sequences, arginine and lysine-rich sequences, and various other sequences of proteins which are secreted despite the absence of a secretion signal sequence, etc.
  • Viral peptide sequences suitable as translocation modules include inter alia viral proteins or partial sequences of viral proteins such as, for example, the protein HIV transcriptional activator protein (HIV tat).
  • the suitable Tat proteins include besides the Tat protein of the HIV 1 virus also the Tat proteins of other lentiviruses. Numerous modified Tat peptides have been described as sequences able to bring about translocation. These include Tat peptides which represent only partial sequences of the Tat protein, e.g.
  • Tat peptides which comprise point mutations Tat peptides in which the sequence is reversed (inverted), or Tat peptides which comprise unusual amino acids such as, for example, D isomers of amino acids, etc.
  • All these variations of peptide sequences are therefore generally suitable as translocation modules.
  • Peptides also suitable for the purposes of the present invention as translocation modules are those derived from other viruses such as, for example, VP22 (herpes simplex virus 1 VP22 tegument protein).
  • VP22 herpes simplex virus 1 VP22 tegument protein
  • commercial expression vectors comprising a VP22 sequence suitable for translocation are also available. These expression vectors therefore permit VP22 fusion proteins to be prepared (VoyagerTM VP22 system, Invitrogen, Breda, the Netherlands).
  • viruses e.g. Marek's disease virus 1
  • a virus which causes lymphoma in chickens also express a protein which is related to VP22 and which is likewise suitable as translocation module.
  • proteins and partial sequences of these proteins are mentioned only as examples, and numerous further peptides are known at present, and will become known in future, which are suitable as translocation modules for the purposes of the invention.
  • translocation modules suitable as translocation modules are peptides derived from the drosophila homeotic protein antennapedia (ANTp).
  • ANTp peptides suitable as translocation module are those comprising an inverted sequence of ANTp, comprising D isomers of amino acids, or comprising point mutations in their sequence. It is additionally expected that numerous further ANTp sequence modifications are also possible and will presumably make translocation possible.
  • ANTp peptide variants are also referred to as transport peptides.
  • engrailed 1 (En1), engrailed 2 (En2), Hoxa 5, Hoxc 8, Hoxb 4 and KNOTTED 1 likewise comprise sequences which can be used as translocation module for the purposes of the present invention.
  • KNOTTED 1 is in fact a plant protein, but is likewise suitable as translocation module in animal cells.
  • These peptides are mentioned only as examples, and numerous further homeoproteins which comprise peptide sequences which may be suitable as translocation module for the purposes of the invention are known. Further previously undisclosed homeoproteins may also comprise sequences suitable as translocation module.
  • Arginine- or lysine-rich peptides suitable as translocation module Arginine-rich peptides represent further peptide sequences which can be used as translocation modules for the purposes of the present invention.
  • sequences are HIV 1 rev- (34-50), flock house virus coat protein FHV coat-(35-49), BMV Gag-(7-25), HTLV-II Rex-(4-15), CCMV Gag-(7-25), P22 N (14-30), lambda N (1-22), phi 21 N-(12-29) and PRP6-(129-144) from yeast.
  • polyarginine peptides having 4 to 16 or else having more than 16 arginine residues.
  • peptides which can also be used as translocation modules are those which, besides arginine, also comprise further amino acids, e.g. the W/R peptide (RRWRRWWRRWWRRWRRWRR) or the R9-Tat peptide in which the 9 central amino acid residues of the total of 11 amino acids of a Tat peptide have been replaced by arginine residues (GRRRRRRRRRQ).
  • peptides which for example consist of nine lysine residues also have the ability to act as translocation module for the purposes of the invention.
  • These peptides are mentioned only as examples and numerous further arginine- or lysine-rich peptides are suitable to be used as translocation module for the purposes of the invention.
  • Further arginine- or lysine-rich peptides currently already known or to become known in future are presumably also suitable as translocation module.
  • Sequences comprising guanidino or amidino groups are also suitable as translocation module for the purposes of the present invention.
  • the amino acids may be naturally occurring amino acids or may be modified amino acids, like chemical derivatives of the amino acids, analogs thereof or D-amino acids.
  • modified amino acids stabilizes the peptide construct and decreases the degradation rate thereof.
  • analog includes any polypeptide having an amino acid residue sequence substantially identical to the sequences used according to the present invention in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the functional aspects of the present invention as described herein.
  • conservative substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another the substitution of one polar (hydrophobilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamin acid or another.
  • conservative substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another
  • substitution of one polar (hydrophobilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine
  • substitution of one basic residue such as lysine, arginine or histidine for another
  • substitution of one acidic residue such as aspartic acid or glutamin acid
  • the term "chemical derivative” refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group.
  • derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p- toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, choioracetyl groups of formyl groups.
  • Free carboxyl groups may be derivatized to from salts, methyl and ethyl esters or other types of esters or hydrazides.
  • Free hydroxyl groups may be derivatized to from O-acyl or O-alkyl derivatives.
  • the imidazole nitrogen of histidine may be derivatized to form N-imbenzylhistidine.
  • chemical derivatives those proteins or peptides, which contain one or more naturally-occurring amino acids derivatives of the twenty standard amino acids.
  • 4-hydroxyproline may be substituted for proline
  • 5-hydroxylsine may be substituted for lysine
  • 3-methylhistidine may be substituted for histidine
  • homoserine may be substituted for serine
  • ornithine may be substituted for lysine.
  • the present invention relates to pharmaceutical compositions comprising the cell or cell line expressing a peptide construct according to the present invention, i.e.
  • the present invention relates to pharmaceutical compositions comprising the antigen-specific T-cells obtainable with the methods according to the present invention.
  • Such pharmaceutical compositions comprise a therapeutically effective amount of the cells and, optionally, a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may be administered with a physiologically acceptable carrier to a subject, as described herein.
  • pharmaceutically acceptable means approved by a regulatory agency or other generally recognized pharmacopoeia for use in animals, and more particularly in humans
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatine, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium, chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • compositions can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium, carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin (18th ed., Mack Publishing Co., Easton, PA (1990)).
  • Such compositions will contain a therapeutically effective amount of the aforementioned cells, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilised powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • compositions for use in connection with the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol.histidine, procaine, etc.
  • “Pharmaceutically or therapeutically acceptable carrier” refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredients and which is not toxic to the host or patient.
  • “Therapeutically- or pharmaceutically-effective amount” as applied to the compositions of the instant invention refers to the amount of composition sufficient to induce a desired biological result. That result can be alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. In the present invention, the result will typically involve e.g. a decrease in the immunological and/or inflammatory responses to infection or tissue injury. In another embodiment, the results include the lysis of tumour cells or other cells expressing or harbouring foreign invaders.
  • the pharmaceutical composition is a vaccine comprising the cell or cell line expressing a peptide construct as defined herein.
  • the cell or cell line is of human origin.
  • the vaccine is for the prevention of host versus graft or graft versus host reactions in transplantation.
  • the vaccines according to the present invention are useful in preventing or treating autoimmune diseases or allergic diseases.
  • the pharmaceutical composition may be used for inducing anergy of antigen-specific T-cells.
  • This is particularly useful in the treatment of autoimmune diseases and allergic diseases.
  • Autoimmune diseases are characterized by self- reactive T cells. Silencing these autoreactive T-cells can be performed by anergizing these cells specifically using aAPCs which anergize these cells rather than stimulate them.
  • Antigen-specific T-cells may be used in adoptive cell transfer therapy, practised as an ex vivo therapy.
  • ex vivo refers to a therapy where biological materials, typically cells, are obtained from a patient or a suitable alternate source, such as, a suitable donor, and are modified, such that the modified cells can be used to treat a disease which will be improved by the therapeutic benefit produced by the modified cells.
  • Treatment includes the re-introduction of the modified biological materials, obtained from either the patient or from the alternate source, into the patient.
  • a benefit of ex vivo therapy is the ability to provide the patient the benefit of the treatment, without exposing the patient to undesired collateral effects from the treatment. For example, high doses of cytokines are often administered to patients with cancer or viral infections to stimulate expansion of the patient's CTLs.
  • cytokines often cause the onset of flu like symptoms in the patients.
  • cytokines are used to stimulate expansion of the CTLs outside of the patient's body, and the patient is spared the exposure and the consequent side effects of the cytokines.
  • the subject can be treated concurrently with low level dosage of Y interferon, ⁇ interferon and/or IL-2.
  • the expected effect of the interferons is to possibly sensitize the tumour cells to lysis by antigen specific CTL 1 and the effect of the IL-2 is to possibly enhance antigen specific CTL persistence.
  • the antigen-specific T-cells obtained by the method according to the present invention are useful for the preparation of a therapeutical composition for the treatment of malignancies, cancer, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host- versus-graft of graft-versus-host reactions in transplantation as well as in tumour therapy.
  • the antigen-specific T-cells are of human origin.
  • aAPC aAPC according to the present invention.
  • These cells can also be used in therapeutical compositions for the treatment of malignancies, cancer, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite disorders, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation, e.g. in tumour therapy.
  • the aAPC When the aAPC are used in pharmaceutical compositions, as a vaccine or in the method for the generation of antigen-specific T-cells, the aAPC are treated in advance to prevent further proliferation of said cells while maintaining their stimulating activity.
  • the aAPC may be irradiated with a sub-lethal dose of radiation.
  • the aAPC are treated with chemical compounds which interfere with the proliferation of the cells without killing them.
  • Other possibilities include a mitomycin-C treatment or UV-irradiation.
  • a pre-treatment step of the aAPC might even enhance later stimulation of T cells. That is, aAPC wherein the cell death program, i.e. induction of apoptosis, has been initiated by a pre-treatment step, like a pre-treatment step as described above, are particularly useful for later administration for in vivo or in vitro co- cultivation with cells comprising T-cells.
  • the present invention relates to methods for treating an infection in a subject comprising the steps of administering the aAPC according to the present invention or the antigen-specific T-cells obtainable according to the present invention to a subject in need of said treatment.
  • the method of treatment may be a vaccination of the subject.
  • the method is an ex vivo adoptive cell transfer therapy of a subject comprising the steps of: a. providing a cell or cell line being phenotypically negative for a functional MHC class I and/or class Il complex; b. introducing a construct comprising (i) a peptide of interest (POI) comprising an antigenic structure, (ii) at least one spacer and (iii) an MHC molecule or parts thereof or sequences encoding (i), (ii) and/or (iii) into the cell or cell line of a.); c.
  • POI peptide of interest
  • the way of administration of the cells is selected from the group consisting of oral, intradermal, subcutaneous, intravenous, inhalative, intranasal, intranodal, or by injection into or near the tumour in case of cancer
  • administered means administration of a therapeutically effective dose of the aforementioned pharmaceutical composition comprising the respective cells to an individual.
  • therapeutically effective amount is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art and described above, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.
  • the methods are applicable to both human therapy and veterinary applications.
  • the compounds described herein having the desired therapeutic activity may be administered in a physiologically acceptable carrier to a patient, as described herein.
  • the compounds may be formulated in a variety of ways as discussed below.
  • concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt%.
  • the agents may be administered alone or in combination with other treatments.
  • the administration of the pharmaceutical composition can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intra-arterial, intranodal, intramedullary, intrathecal, intraventricular, intranasally, intrabronchial, transdermal ⁇ , intranodally, intrarectally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly.
  • dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
  • the present invention relates to a kit for the generation and expansion of antigen-specific T-cells
  • a cell or cell line which is an aAPC and/or b. a cell or cell line being phenotypically negative for a functional MHC class I and/or MHCclass Il complex; c. a construct as defined above for expressing a peptide construct comprising the antigenic structure presented by an MHC molecule ,and d. instructions for conducting the method according to the present invention.
  • the kit for the generation and expansion of antigen-specific T-cells comprises a. a construct as defined above, b. molecules suppressing the expression of functional self MHC class I or class Il complex.e.g. RNAi, and c. instructions how the use the kit for generating and expanding antigen-specific T-cells.
  • Figure 1 (A) the design of a construct for transfection of cells being phenotypically negative for a functional MHC class I and/or class Il complex is exemplied.
  • the sequence of the modules is as follows: human ⁇ 2m signal peptide, POI, spacer 1 , human ⁇ 2m, spacer 2, HLA- A2.1 , transmembrane region of the HLA-molecule, cytoplsamic region of the HLA-molecule.
  • the sites for the restriction enzymes is exemplied.
  • FIG. 2 Scheme of the ex vivo generation of antigen-specific T-cells according to the present invention.
  • Blood is isolated from e.g. the individual to be treated.
  • the PBMC are isolated via a Ficoll gradient.
  • the obtained PBMC are co-cultured with aAPC obtained according to the present invention, preferably by repeating the co-culturing at least once to obtain a sufficient number of peptide specific T cells.
  • the aAPC are obtained by transfecting MHC negative cells with the construct comprising the POI and MHC molecule which may contain additional spacer. Transfection may be achieved by electroporation or other suitable methods for introducing DNA or fusion proteins into a cell.
  • these cells are pre-treated before co-cultivation, e.g. by irradiation.
  • the analysis of the amount and the ratio of peptide specific T cells obtained after co-cultivation may be conducted by methods known in the art, e.g. by flow cytometry.
  • Figure 3 The amount of antigen (peptide)-specific T cells after several cycles of co-cultivation is shown. Antigen-specific T cells are detected by intracellular IFN-g staining and CD8 staining after peptide stimulation.
  • the amount of antigen-specific T cells was about 0,07%. After 3 weeks the amount of antigen-specific T-cells increased to 22,38 % and after 7 weeks antigen-specific T cells represented about 83,83% of the cells.
  • Figure 4 is a diagram showing the cytotoxic activity of the generated antigen-specific T cells. Shown is the specific lysis of target cells loaded with the specific antigenic peptide, the antigen-specific cells were raised against said peptide according to the method of the present invention. Shown is specific lysis in percentage at varying amounts of peptide
  • the construct was basically produced as described in Greten et al., J. Immunol. Meth., 2002, 125-135 which is herein incorporated by reference in its entirety.
  • the construct was further modified by introducing a sequence coding for GFP at the 3'- end of the construct, thus, allowing easy detection and selection of transfected cells.
  • the construct was introduced into Daudi cells (ATCC NO. CCL 213) by electroporation with 10 ⁇ g of the plasmid containing the construct (Gene Pulser, BioRad) following manufacturers instructions.
  • PBMC peripheral blood mononuclear cells
  • aAPCs obtained in Example 2 were pre-stimulated with Co- stimulatory compounds.
  • 1 x 10E06 Daudi aAPC were cultured in AB- medium (fully supplemented RPMI 16340 medium wherein AB-sera is supplemented instead of FCS) supplemented with 500 IU/ml IL-4 and 1 x 10E05 NIH3t3 CD40L cells, which express the CD40L molecule on their surface, in 1 ml in a 24 well plate for 24 h.
  • the aAPC were irradiated with 80 Gy, washed in PBS and resuspended to a final concentration of 4 x 10E05/ml.
  • 0,5 ml PBMC and 0,5 ml aAPC were plated into one well of a 48 well plate.
  • the cells were incubated at 37°C in humidified air with 5% CO2. After 24 h 10cll/ml human recombinant IL-2 was added and cultivation was continued.
  • the cytotoxic activity of the generated antigen-specific T cells was determined with the well known Cr51 release assay.
  • the effector/target ratio was 20:1 That is, 20 times more antigen-specific T-cells were co-cultured with peptide loaded target cells.
  • Another construct useful for the generation and expansion of antigen-specific T cells according to the present invention is a construct containing the well known NY-ESO- Epitope SLLMWITQC derived from the germ cell antigen NY-ESO which is frequently expressed in cancer.
  • This epitope is an HLA-A2 restricted peptide derived from the cancer testis antigen NY-ESO-1 , which is a tumour antigen known to be expressed in melanoma, esophageal cancer, liver cancer, neuroblastoma, testicular carcinoma, multiple myeloma, sarcoma, ovarian cancer, breast cancer, non.small cell lung cancer, prostate cancer, bladder cancer.
  • the construct containing the NY-ESO-Epitope is produced by substituting the influenza M1 peptide present in the construct described in Example 1 with a nucleic acid sequence encoding the NY-ESO Epitope.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne la génération et l'expansion de lymphocytes T spécifiques d'antigène. En outre, la présente invention concerne l'utilisation de lymphocytes T spécifiques d'antigène obtenus au moyen de la méthode de l'invention dans une thérapie par transfert adoptif de cellules et dans le traitement de divers troubles et maladies tels que les infections et le cancer. De plus, la présente invention concerne des trousses et leur utilisation pour la génération et l'expansion de lymphocytes T spécifiques d'antigène. La présente invention permet la génération de lymphocytes T spécifiques d'antigène adaptés à un transfert adoptif de cellules. Les méthodes de génération et d'expansion de lymphocytes T spécifiques d'antigène comprennent des approches in vitro et in vivo.
PCT/EP2005/009289 2005-08-29 2005-08-29 Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes WO2007025554A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/009289 WO2007025554A1 (fr) 2005-08-29 2005-08-29 Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes
PCT/EP2006/008421 WO2007025705A2 (fr) 2005-08-29 2006-08-29 Procede de production de lymphocytes t specifiques a l'antigene et utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/009289 WO2007025554A1 (fr) 2005-08-29 2005-08-29 Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes

Publications (1)

Publication Number Publication Date
WO2007025554A1 true WO2007025554A1 (fr) 2007-03-08

Family

ID=35241189

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/009289 WO2007025554A1 (fr) 2005-08-29 2005-08-29 Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes
PCT/EP2006/008421 WO2007025705A2 (fr) 2005-08-29 2006-08-29 Procede de production de lymphocytes t specifiques a l'antigene et utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008421 WO2007025705A2 (fr) 2005-08-29 2006-08-29 Procede de production de lymphocytes t specifiques a l'antigene et utilisations

Country Status (1)

Country Link
WO (2) WO2007025554A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501521B2 (en) 2012-12-21 2019-12-10 Hoffmann-La Roche Inc. Disulfide-linked multivalent MHC class I comprising multi-function proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013095A2 (fr) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Utilisation de molecules polyvalentes du type complexe majeur d'histocompatibilite (cmh)/immoglobuline (ig) chargees en peptides chimeres pour deceler, activer ou supprimer les reponses immunes dependant des cellules t specifiques de l'antigene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013095A2 (fr) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Utilisation de molecules polyvalentes du type complexe majeur d'histocompatibilite (cmh)/immoglobuline (ig) chargees en peptides chimeres pour deceler, activer ou supprimer les reponses immunes dependant des cellules t specifiques de l'antigene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUDLEY MARK E ET AL: "Adoptive-cell-transfer therapy for the treatment of patients with cancer.", NATURE REVIEWS CANCER, vol. 3, no. 9, September 2003 (2003-09-01), pages 666 - 675, XP002353828, ISSN: 1474-175X *
GRETEN T F ET AL: "Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 271, no. 1-2, 20 December 2002 (2002-12-20), pages 125 - 135, XP004393932, ISSN: 0022-1759 *
MÄRTEN ANGELA ET AL: "Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. MAR 2002, vol. 51, no. 1, March 2002 (2002-03-01), pages 25 - 32, XP002354938, ISSN: 0340-7004 *
OELKE MATHIAS ET AL: "Technological advances in adoptive immunotherapy", DRUGS OF TODAY, vol. 41, no. 1, January 2005 (2005-01-01), pages 13 - 21, XP009056991, ISSN: 0025-7656 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501521B2 (en) 2012-12-21 2019-12-10 Hoffmann-La Roche Inc. Disulfide-linked multivalent MHC class I comprising multi-function proteins

Also Published As

Publication number Publication date
WO2007025705A2 (fr) 2007-03-08
WO2007025705A3 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
US11098284B2 (en) Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
RU2709711C2 (ru) Новые иммуногенные пептиды
Porgador et al. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
ES2842878T3 (es) Generación de células T específicas de antígeno
ES2302707T3 (es) Activacion del sistema inmunitario por un inductor nf-kappa b y un antigeno.
US11975025B2 (en) Viral vectors and use thereof in adoptive cellular therapy
US20090297541A1 (en) Maturation of dendritic cells
US20060073159A1 (en) Human anti-cancer immunotherapy
US20180305666A1 (en) Methods for generating engineered human primary blood dendritic cell lines
JP2019520823A (ja) メモリーｔ細胞から作られるベト細胞
JP2018531022A6 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
US8232101B2 (en) Identification of antigenic peptides from multiple myeloma cells
US20230151384A1 (en) Nf-kb signalign pathway-manipulated dendritic cells
US20120251579A1 (en) Compositions for generating an antigen specific immune response
WO2020145222A1 (fr) Nouveaux néoantigènes et immunothérapie anticancéreuse l'utilisant
WO2003039594A2 (fr) Vesicules porteuses d'antigene
US20070161108A1 (en) Bob-1 specific T cells and methods to use
CA2432542A1 (fr) Procedes
WO2007025554A1 (fr) Methode de generation de lymphocytes t specifiques d'antigene et utilisations correspondantes
US20130337001A1 (en) Immunogenic composition for treatment of hepatitis C, a method for preparing the composition and use thereof for treating hepatitis C
US20230355678A1 (en) Methods for improving t cell efficacy
Liu NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections
Nayak Antigen delivery to dendritic cell populations: Internalization, antigen presentation and functional consequences for regulating immune responses
JP2001026545A (ja) 免疫応答活性化製剤
MXPA94005978A (en) Methods for ex vivo therapy using antigen depressed cells charged with peptide for the application of

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05781634

Country of ref document: EP

Kind code of ref document: A1